MediWound Q1 Revenue Falls 15%, But Shares Jump on Reaffirmed 2026 Outlook

MediWound (NASDAQ: MDWD) reported a 15% drop in first-quarter revenue to $4.2 million, missing analyst expectations of $4.5 million, on May 28, 2026. However, the company reiterated its full-year 2026 revenue target of $22 million to $25 million, citing upcoming milestones for its NexoBrid burn treatment. The reaffirmed forecast triggered a sharp rally, with shares climbing over 8% in early trading, as investors focused on the maintained long-term outlook despite near-term softness. CEO Ofer Gonen said the pipeline progress remains on track, with European regulatory submissions expected in the second half of the year. The company had previously warned of quarterly volatility due to the timing of international orders.